Keytruda+Lenvima – Flight 1- RCC Display Banners Therapeutic Spotlight – 590751
RCC eBook
Focus on Renal Cell Carn.indd
RN-VT Outcomes for Patients With Renal Cell Carcinoma
Following radical nephrectomy and venous thrombectomy (RN-VT), patients with renal cell carcinoma...
Metastatic Renal Cell Carcinoma Outcomes Linked With CT Texture Analysis
In metastatic renal cell carcinoma (mRCC), immune checkpoint inhibitor treatment responses vary,...
Renal Cell Carcinoma & Deep Invasive Tumor Thrombus: Predicting Surgical Complications
Radical nephrectomy and thrombectomy can effectively improve the prognosis of the 4% to 10% of...
Construction of an immune-related prognostic model by exploring the tumor microenvironment of clear cell renal cell carcinoma.
In this study, bioinformatics methods were performed to screen the candidate prognosis-related...
Pembrolizumab Bests TKIs for Treating High-Risk Renal Cell Carcinoma
A study published in the European Urology Oncology reports superior oncologic and safety benefits of adjuvant pembrolizumab compared with adjuvant tyrosine kinase inhibitors (TKIs) in patients treated with nephrectomy for...
Apigenin inhibits renal cell carcinoma cell proliferation through G2/M phase cell cycle arrest.
Apigenin is a flavonoid widely presented in fruits and vegetables, and is known to possess anti‑inflammatory, antioxidant, and anticancer properties. The present study was designed to investigate the effects of apigenin on renal...
A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression.
. Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a rare aggressive renal malignancy associated with hereditary leiomyomatosis and RCC syndrome (HLRCC). Tumors exhibiting heterogeneous (ie, patchy) FH loss by...
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
In the CheckMate 9ER trial, patients with advanced renal cell carcinoma who received first-line nivolumab plus cabozantinib had significantly better progression-free survival compared with those given sunitinib. In this study,...
Renal Cell Carcinoma and Other Renal Masses in Kidney Graft Patients
Renal masses in kidney grafts provide a difficult clinical problem, as they must balance graft function with the necessity for cancer management. Cancers in the renal graft caused by donors can be classed as either ‘donor...
MicroRNAs in The Urine: A Potential New Tool for Renal Cancer Diagnosis, Prognosis, and Monitoring
Renal cell carcinoma is the third most prevalent kind of urologic cancer. Because the first symptoms are often vague and late, the phases are often advanced when detected. As compensation, the discovery of RCC by abdominal...
